What's Happening?
The National Institute for Health and Care Excellence (NICE) has reversed its earlier decision and now supports the use of Genmab's Tivdak (tisotumab vedotin) for adults with recurrent or metastatic cervical cancer in the UK. Initially, NICE had concerns
about the economic model presented by Genmab, which led to a decision against recommending the drug. However, after revisions to the economic model and additional data from the innovaTV 301 trial, NICE has approved Tivdak for use. The trial showed that Tivdak improved median overall survival to 11.5 months compared to 9.5 months with chemotherapy. This decision is significant as it provides a new treatment option for patients with limited alternatives.
Why It's Important?
This decision is crucial for patients with recurrent or metastatic cervical cancer, who have limited treatment options beyond chemotherapy. The approval of Tivdak offers a potential improvement in survival outcomes, addressing an urgent need in this patient population. For Genmab, this approval marks a significant milestone as Tivdak is the first product launched independently by the company. The drug's approval could lead to increased revenues, with analysts predicting potential peak global sales of $600 million. The decision also highlights the importance of real-world evidence and economic modeling in gaining approval for new therapies.
What's Next?
With NICE's approval, Tivdak will initially be covered by the Cancer Drugs Fund before routine NHS commissioning. Genmab plans to work closely with the NHS, clinicians, and patient groups to ensure timely access and smooth implementation of the drug. The company is also preparing for a broader rollout in Europe, which could further boost its market presence and financial performance. The success of Tivdak could encourage Genmab to pursue more independent product launches in the future.
